Investegate announcements from F. Hoffmann-La Roche Ltd, New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq
EMA's CHMP recommended the approval yesterdayApproval based on results from four phase III studies in over 5,500 patientsActemra/RoActemra has also been provisionally approved in Australia for the treatment
Actemra/RoActemra reduced the risk of death in patients with severe COVID-19, as evidenced by a review of four phase III studiesThe European Commission is expected to make a final decision regarding approval
06.12.2021 - Basel, 6 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it completed the repurchase of Roche shares that had been held by Novartis. On 4 November 2021, Roche and Novartis had announced this repurchase. The Extraordinary .